{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:14:33Z","timestamp":1793171673285,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejmech.2024.116787","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T03:39:04Z","timestamp":1724729944000},"page":"116787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Development of fibroblast activation protein-\u03b1 radiopharmaceuticals: Recent advances and perspectives"],"prefix":"10.1016","volume":"277","author":[{"given":"Ziyue","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3515-3827","authenticated-orcid":false,"given":"Zehui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116787_bib1","doi-asserted-by":"crossref","first-page":"36505","DOI":"10.1074\/jbc.274.51.36505","article-title":"Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts","volume":"274","author":"Park","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2024.116787_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11886-023-01869-8","article-title":"The potential of fibroblast activation protein-targeted imaging as a biomarker of cardiac remodeling and injury","volume":"25","author":"Mayola","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.ejmech.2024.116787_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1064157","article-title":"Circulating fibroblast activation protein \u03b1 is reduced in acute ischemic stroke","volume":"9","author":"Sieweke","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib5","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/j.humpath.2013.06.016","article-title":"Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer","volume":"44","author":"Tchou","year":"2013","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ejmech.2024.116787_bib6","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20220463","article-title":"Non-oncologic incidental uptake on FAPI PET\/CT imaging","volume":"96","author":"Hotta","year":"2023","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ejmech.2024.116787_bib7","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.220749","article-title":"Fapi PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.ejmech.2024.116787_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41583-021-00525-w","article-title":"Emerging roles for CNS fibroblasts in health, injury and disease","volume":"23","author":"Dorrier","year":"2022","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2024.116787_bib9","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.3390\/cancers13225744","article-title":"Radioligands targeting fibroblast activation protein (FAP)","volume":"13","author":"Lindner","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116787_bib10","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.122.264205","article-title":"Fibroblast activation protein inhibitor imaging in nonmalignant diseases: a new perspective for molecular imaging","volume":"63","author":"Schmidkonz","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib11","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.7150\/thno.69475","article-title":"Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review","volume":"12","author":"Zhao","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2024.116787_bib12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s13402-023-00872-z","article-title":"From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment","volume":"47","author":"Zhang","year":"2024","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ejmech.2024.116787_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41181-019-0069-0","article-title":"Targeting of activated fibroblasts for imaging and therapy","volume":"4","author":"Lindner","year":"2019","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib14","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/ijms24043863","article-title":"Fibroblast activation protein inhibitor (FAPI)-Based theranostics\u2014where we are at and where we are heading: a systematic review","volume":"24","author":"Sidrak","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116787_bib15","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1007\/s00259-022-05706-y","article-title":"Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond","volume":"49","author":"Li","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib16","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Priv\u00e9","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib17","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.1994.12.6.1193","article-title":"Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts","volume":"12","author":"Welt","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116787_bib18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib19","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib20","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib21","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2024.116787_bib22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera(\u00ae): the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2024.116787_bib23","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib24","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s00259-023-06169-5","article-title":"A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy","volume":"50","author":"Yang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib26","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s00259-021-05653-0","article-title":"Translational imaging of the fibroblast activation protein (FAP) using the new ligand [(68)Ga]Ga-OncoFAP-DOTAGA","volume":"49","author":"Backhaus","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101852118","article-title":"An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications","volume":"118","author":"Millul","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2024.116787_bib28","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00259-023-06272-7","article-title":"Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides","volume":"50","author":"Millul","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2967\/jnumed.123.266345","article-title":"Preclinical development of PNT6555, a boronic acid-based, fibroblast activation protein-\u03b1 (FAP)-Targeted radiotheranostic for imaging and treatment of FAP-positive tumors","volume":"65","author":"Poplawski","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/ph16030449","article-title":"Novel (68)Ga-labeled pyridine-based fibroblast activation protein-targeted tracers with high tumor-to-background contrast","volume":"16","author":"Verena","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2024.116787_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116238","article-title":"Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-\u03b1-targeted radiotheranostic for cancer imaging and therapy","volume":"268","author":"Bendre","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib32","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.3390\/molecules28083481","article-title":"Synthesis and evaluation of 68Ga-labeled (2S,4S)-4-Fluoropyrrolidine-2-Carbonitrile and (4r)-thiazolidine-4-carbonitrile derivatives as novel fibroblast activation protein-targeted PET tracers for cancer imaging","volume":"28","author":"Bendre","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116787_bib33","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1021\/acssensors.1c01316","article-title":"Rational design, pharmacomodulation, and synthesis of [68Ga]Ga-Alb-FAPtp-01, a selective tumor-associated fibroblast activation protein tracer for PET imaging of glioma","volume":"6","author":"Lin","year":"2021","journal-title":"ACS Sens."},{"key":"10.1016\/j.ejmech.2024.116787_bib34","doi-asserted-by":"crossref","DOI":"10.1021\/acs.bioconjchem.4c00214","article-title":"Development of an FAP-targeted PET probe based on a novel quinolinium molecular scaffold","author":"Li","year":"2024","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib35","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116787_bib36","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.4c00327","article-title":"Development and evaluation of DOTA-FAPI-maleimide as a novel radiotracer for tumor theranostic with extended circulation","author":"Feng","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41181-020-00102-z","article-title":"Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators","volume":"5","author":"Moon","year":"2020","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib38","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1021\/acs.molpharmaceut.3c00248","article-title":"Fibroblast activation protein targeting probe with Gly\u2013pro sequence for PET of glioblastoma","volume":"20","author":"Lai","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib39","doi-asserted-by":"crossref","first-page":"8614","DOI":"10.1021\/acs.jmedchem.3c00259","article-title":"High affinity and FAP-targeted radiotracers: a potential design strategy to improve the pharmacokinetics and tumor uptake for FAP inhibitors","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib40","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1021\/acs.molpharmaceut.3c01008","article-title":"Preclinical evaluation and a pilot clinical positron emission tomography imaging study of [68Ga]Ga-FAPI-FUSCC-II","volume":"21","author":"Du","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2967\/jnumed.122.264494","article-title":"Fibroblast activation protein-targeted radioligand therapy for treatment of solid tumors","volume":"64","author":"Lindeman","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib42","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1021\/acs.jmedchem.4c00448","article-title":"FAP radioligand linker optimization improves tumor dose and tumor-to-healthy organ ratios in 4T1 syngeneic model","volume":"67","author":"Lindeman","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib43","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1007\/s00259-022-05757-1","article-title":"(18)F- or (177)Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention","volume":"49","author":"Li","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib44","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2967\/jnumed.122.264036","article-title":"A dimeric FAP-targeting small-molecule radioconjugate with high and prolonged tumor uptake","volume":"63","author":"Galbiati","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib45","doi-asserted-by":"crossref","first-page":"13392","DOI":"10.1021\/acs.jmedchem.4c01295","article-title":"Molecular evolution of multivalent OncoFAP derivatives with enhanced tumor uptake and prolonged tumor retention","volume":"67","author":"Galbiati","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib46","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2967\/jnumed.121.263016","article-title":"Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of (68)Ga-labeled FAPI dimer","volume":"63","author":"Zhao","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib47","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.123.265599","article-title":"Development of FAPI tetramers to improve tumor uptake and efficacy of FAPI radioligand therapy","volume":"64","author":"Pang","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib48","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1021\/acs.molpharmaceut.2c01112","article-title":"[68Ga]Ga-HBED-CC-FAPI derivatives with improved radiolabeling and specific tumor uptake","volume":"20","author":"Hong","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/thno.68182","article-title":"Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics","volume":"12","author":"Wen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2024.116787_bib50","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00259-021-05591-x","article-title":"Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy","volume":"49","author":"Zhang","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib51","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1021\/acs.molpharmaceut.2c00579","article-title":"86Y-Labeled albumin-binding fibroblast activation protein inhibitor for late-time-point cancer diagnosis","volume":"19","author":"Ding","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib52","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2967\/jnumed.121.262533","article-title":"Albumin binder-conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy","volume":"63","author":"Xu","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib53","doi-asserted-by":"crossref","first-page":"8245","DOI":"10.1021\/acs.jmedchem.1c02162","article-title":"Rational design and pharmacomodulation of protein-binding theranostic radioligands for targeting the fibroblast activation protein","volume":"65","author":"Meng","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib54","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s11307-021-01593-1","article-title":"A trifunctional theranostic ligand targeting fibroblast activation protein-\u03b1 (FAP\u03b1)","volume":"23","author":"Kelly","year":"2021","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.ejmech.2024.116787_bib55","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.2967\/jnumed.120.242958","article-title":"Targeting fibroblast activation protein: radiosynthesis and preclinical evaluation of an (18)F-labeled FAP inhibitor","volume":"61","author":"Toms","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib56","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1021\/acsptsci.3c00187","article-title":"Design, synthesis, and evaluation of 18F-labeled tracers targeting fibroblast activation protein for brain imaging","volume":"6","author":"Yu","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2024.116787_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115862","article-title":"Next generation fibroblast activation protein (FAP) targeting PET tracers - the tetrazine ligation allows an easy and convenient way to (18)F-labeled (4-quinolinoyl)glycyl-2-cyanopyrrolidines","volume":"262","author":"Poulie","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib58","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1021\/acs.jmedchem.3c02402","article-title":"Druglike, 18F-labeled PET tracers targeting fibroblast activation protein","volume":"67","author":"Tanc","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s41181-021-00144-x","article-title":"18F-labeled tracers targeting fibroblast activation protein","volume":"6","author":"Lindner","year":"2021","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115993","article-title":"Synthesis and preclinical evaluation of novel 18F-labeled fibroblast activation protein tracers for positron emission tomography imaging of cancer-associated fibroblasts","volume":"264","author":"Zhou","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib61","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.apsb.2021.09.032","article-title":"Preclinical evaluation and pilot clinical study of [18F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts","volume":"12","author":"Hu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116787_bib62","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1007\/s00259-023-06282-5","article-title":"Noninvasive imaging of FAP expression using positron emission tomography: a comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42","volume":"50","author":"Huang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106878","article-title":"Radiosynthesis, preclinical evaluation and pilot clinical PET imaging study of a 18F-labeled tracer targeting fibroblast activation protein","volume":"141","author":"Fu","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib64","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1007\/s00259-023-06230-3","article-title":"Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy","volume":"50","author":"Liu","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib65","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2967\/jnumed.119.239731","article-title":"Design and development of (99m)Tc-labeled FAPI tracers for SPECT imaging and (188)Re therapy","volume":"61","author":"Lindner","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib66","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/molecules27010264","article-title":"Design, synthesis and preclinical assessment of 99mTc-iFAP for in vivo fibroblast activation protein (FAP) imaging","volume":"27","author":"Trujillo-Ben\u00edtez","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116787_bib67","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s00259-022-06068-1","article-title":"The role of [99mTc]Tc-HFAPi SPECT\/CT in patients with malignancies of digestive system: first clinical experience","volume":"50","author":"Jia","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib68","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1021\/acs.molpharmaceut.1c00712","article-title":"Preparation and bioevaluation of (99m)Tc-labeled FAP inhibitors as tumor radiotracers to target the fibroblast activation protein","volume":"19","author":"Ruan","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib69","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1021\/acs.molpharmaceut.2c01094","article-title":"A simple kit formulation for preparation and exploratory human studies of a novel 99mTc-labeled fibroblast activation protein inhibitor tracer for imaging of the fibroblast activation protein in cancers","volume":"20","author":"Ruan","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib70","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1021\/acs.jmedchem.2c02062","article-title":"Synthesis and evaluation of 99mTc-labeled FAP inhibitors with different linkers for imaging of fibroblast activation proteins in tumors","volume":"66","author":"Ruan","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib71","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1021\/acs.jmedchem.4c00031","article-title":"Synthesis and preclinical evaluation of novel 99mTc-labeled FAPI-46 derivatives with significant tumor uptake and improved tumor-to-nontarget ratios","volume":"67","author":"Ruan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib72","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1021\/acs.bioconjchem.3c00442","article-title":"Formulation and preclinical testing of Tc-99m-Labeled HYNIC-Glc-FAPT as a FAP-targeting tumor radiotracer","volume":"34","author":"Yang","year":"2023","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib73","doi-asserted-by":"crossref","first-page":"8460","DOI":"10.1021\/acs.jmedchem.4c00772","article-title":"Rational design and comparison of novel 99mTc-labeled FAPI dimers for visualization of multiple tumor types","volume":"67","author":"Meng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib74","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.7150\/thno.41409","article-title":"Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents","volume":"10","author":"Roy","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2024.116787_bib75","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1021\/acs.molpharmaceut.1c00566","article-title":"Synthesis and preliminary evaluation of 131I-labeled FAPI tracers for cancer theranostics","volume":"18","author":"Ma","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib76","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1007\/s00259-022-05933-3","article-title":"Hetero-bivalent agents targeting FAP and PSMA","volume":"49","author":"Boinapally","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib77","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/ph15030383","article-title":"Radiosynthesis and preclinical evaluation of bispecific PSMA\/FAP heterodimers for tumor imaging","volume":"15","author":"Hu","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2024.116787_bib78","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1021\/acs.molpharmaceut.2c01000","article-title":"Preclinical evaluation of a fibroblast activation protein and a prostate-specific membrane antigen dual-targeted probe for noninvasive prostate cancer imaging","volume":"20","author":"Wang","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib79","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/molecules28031088","article-title":"Synthesis and preclinical evaluation of three novel 68Ga-labeled bispecific PSMA\/FAP-Targeting tracers for prostate cancer imaging","volume":"28","author":"Verena","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116787_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115279","article-title":"Synthesis and preclinical evaluation of a heterodimeric radioligand targeting fibroblast activation protein and integrin-\u03b1(v)\u03b2(3)","volume":"251","author":"Yan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib81","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2967\/jnumed.123.266183","article-title":"Design, preclinical evaluation, and clinical translation of (68)Ga-FAPI-LM3, a heterobivalent molecule for PET imaging of nasopharyngeal carcinoma","volume":"65","author":"Zhao","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib82","doi-asserted-by":"crossref","first-page":"8361","DOI":"10.1021\/acs.jmedchem.4c00544","article-title":"Rational design and pharmacomodulation of 18F-labeled biotin\/FAPI-conjugated heterodimers","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib83","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00259-023-06338-6","article-title":"Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?","volume":"50","author":"Chakravarty","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib84","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","article-title":"The uniqueness of albumin as a carrier in nanodrug delivery","volume":"18","author":"Spada","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib85","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold","volume":"4","author":"Jansen","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116787_bib86","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/jm500031w","article-title":"Extended structure\u2013activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)","volume":"57","author":"Jansen","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib87","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2967\/jnumed.119.233122","article-title":"Theranostics targeting fibroblast activation protein in the tumor stroma: (64)Cu- and (225)Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models","volume":"61","author":"Watabe","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib88","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib89","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.122.264544","article-title":"PET imaging of fibroblast activation protein in various types of cancer using (68)Ga-FAP-2286: comparison with (18)F-FDG and (68)Ga-FAPI-46 in a single-center, prospective study","volume":"64","author":"Pang","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib90","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s00259-020-04990-w","article-title":"A theranostic approach of [(68)Ga]Ga-DOTA.SA.FAPi PET\/CT-guided [(177)Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy","volume":"48","author":"Ballal","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib91","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1097\/RLU.0000000000004563","article-title":"68 Ga-DOTA.SA.FAPI as a potential, noninvasive diagnostic probe for recurrent and metastatic adrenocortical carcinoma : a head-to-head comparison with 18F-FDG","volume":"48","author":"Chopra","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib92","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1021\/acs.molpharmaceut.2c00965","article-title":"Synthesis and preclinical evaluation of a novel FAPI-04 dimer for cancer theranostics","volume":"20","author":"Zhong","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib93","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3390\/cancers15061889","article-title":"Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116787_bib94","first-page":"476","article-title":"Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time","volume":"11","author":"Moon","year":"2021","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ejmech.2024.116787_bib95","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1021\/acs.molpharmaceut.2c00424","article-title":"Development of fibroblast activation protein inhibitor-based dimeric radiotracers with improved tumor retention and antitumor efficacy","volume":"19","author":"Zhao","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib96","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/acs.bioconjchem.8b00919","article-title":"Bench to bedside: albumin binders for improved cancer radioligand therapies","volume":"30","author":"Lau","year":"2019","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2024.116787_bib97","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1007\/s00259-021-05470-5","article-title":"Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging","volume":"48","author":"Wang","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2024.116787_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.802676","article-title":"Automatic production and preliminary PET imaging of a new imaging agent [(18)F]AlF-FAPT","volume":"11","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116787_bib99","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1021\/acs.molpharmaceut.3c00886","article-title":"Synthesis and preliminary study of 99mTc-labeled HYNIC-FAPi for imaging of fibroblast activation proteins in tumors","volume":"21","author":"Ma","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116787_bib100","article-title":"Development of [68Ga]Ga\/[177Lu]Lu-DOTA-NI-FAPI-04 containing nitroimidazole moiety as new FAPI radiotracers with improved tumor uptake and retention","volume":"65","author":"Luo","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib101","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/pros.24549","article-title":"PSMA-heterogeneity in metastatic castration-resistant prostate cancer: circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy","volume":"83","author":"Derlin","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.ejmech.2024.116787_bib102","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3390\/cancers12061367","article-title":"PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy","volume":"12","author":"Jones","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116787_bib103","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2967\/jnumed.123.265594","article-title":"Fibroblast activation protein inhibitor\u2013based radionuclide therapies: current status and future directions","volume":"64","author":"Ora","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2024.116787_bib104","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.122.265383","article-title":"Clinical evaluation of (68)Ga-FAPI-RGD for imaging of fibroblast activation protein and integrin \u03b1(v)\u03b2(3) in various cancer types","volume":"64","author":"Zhao","year":"2023","journal-title":"J. Nucl. Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424006688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424006688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T12:15:37Z","timestamp":1738412137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424006688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":104,"alternative-id":["S0223523424006688"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116787","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of fibroblast activation protein-\u03b1 radiopharmaceuticals: Recent advances and perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116787"}}